secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001140361-24-037073
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotechnology enters $50M ATM equity offering program with B. Riley and H.C. Wainwright
--------------------------------------------------------------------------------

- New at-the-market sales agreement allows up to $50M in common stock through B. Riley Securities and H.C. Wainwright.
- Replaces prior August 2022 ATM program; 3% commission on gross proceeds to agents.
- Shares sold via Rule 415 at-the-market on Nasdaq Capital Market; no minimum sales obligation.
- Prior ATM agreement with B. Riley and BTIG terminated effective August 13, 2024.
- Proceeds from any future sales will be used for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124037073/0001140361-24-037073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124037073/ny20034050x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-037073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer